Explore the vast range of titles available.

Neuroendocrine prostate cancer is an aggressive variant of prostate cancer that may arise de novo or develop from pre-existing prostate adenocarcinoma as a mechanism of treatment resistance. The combined loss of tumor suppressors RB1, TP53, and PTEN are frequent in NEPC but also present in a subset of prostate adenocarcinomas. Most clinical and preclinical studies support a trans-differentiation process, whereby NEPC arises clonally from a prostate adenocarcinoma precursor during the course of treatment resistance. Here we highlight a case of NEPC with significant intra-patient heterogeneity observed across metastases. We further demonstrate how single-cell genomic analysis of circulating tumor cells combined with a phenotypic evaluation of cellular diversity can be considered as a window into tumor heterogeneity in patients with advanced prostate cancer.

Kristy Quirk, 36, and her mum Sue Altmann, 66, and their friend Peppie Simpson, 53, have been practising their synchronised ballet moves on longboards.

Sunshine Coast brothers Jesse and Jye Parkinson, aged 7 and 9, are leading a new wave of fearless mini-surfers, dubbed \"micro grommets\".

Social prescribing is an approach that aims to improve health and well-being. It connects individuals to non-clinical services and supports that address social needs, such as those related to loneliness, housing instability and mental health. At the person level, social prescribing can give individuals the knowledge, skills, motivation and confidence to manage their own health and well-being. At the society level, it can facilitate greater collaboration across health, social, and community sectors to promote integrated care and move beyond the traditional biomedical model of health. While the term social prescribing was first popularised in the UK, this practice has become more prevalent and widely publicised internationally over the last decade. This paper aims to illuminate the ways social prescribing has been conceptualised and implemented across 17 countries in Europe, Asia, Australia and North America. We draw from the ‘Beyond the Building Blocks’ framework to describe the essential inputs for adopting social prescribing into policy and practice, related to service delivery; social determinants and household production of health; workforce; leadership and governance; financing, community organisations and societal partnerships; health technology; and information, learning and accountability. Cross-cutting lessons can inform country and regional efforts to tailor social prescribing models to best support local needs.

Neuroimaging research requires purpose-built analysis software, which is challenging to install and may produce different results across computing environments. The community-oriented, open-source Neurodesk platform ( https://www.neurodesk.org/ ) harnesses a comprehensive and growing suite of neuroimaging software containers. Neurodesk includes a browser-accessible virtual desktop, command-line interface and computational notebook compatibility, allowing for accessible, flexible, portable and fully reproducible neuroimaging analysis on personal workstations, high-performance computers and the cloud. Neurodesk is a platform for analyzing human neuroimaging data, which provides numerous tools in a containerized form, thereby ensuring reproducibility and portability.

Functional Neurological Disorder (FND) can present significant management challenges due to its sometimes-complex presentation and the historical stigma attached to this diagnosis. Recent advances have improved understanding and management of FND, emphasising the benefit of a multidisciplinary approach to management. The prognosis of FND varies but evidence-based treatments offer the potential of remission to many people for whom FND might otherwise cause long-term disability, and meaningful symptomatic and functional improvement for many more. Despite this, limited and inequitable access to treatment means that many people with FND in Australia continue to experience treatable disability due to the condition.Diagnosis: FND should be diagnosed based on positive signs rather than exclusion. This includes identifying inconsistencies and incongruencies in symptoms that differentiate them from other neurological conditions.Communication: The diagnosis of FND should be communicated to patients promptly and clearly upon diagnosis of the condition. Information provided should include the name of the condition, the basis on which the diagnosis has been made, key principles that can aid self-management, and shared planning of next steps in treatment or accessing treatment.Multidisciplinary Management: Across healthcare service models, treatment should involve a multidisciplinary team to address the multifaceted, and sometimes complex symptoms of FND.Role of General Practitioners (GPs): GPs are integral in the long-term management of FND, providing continuity of care, patient support and education, and facilitating access to specialist services. An informed GP can provide the patient with confidence and agency to be pro-active in their symptoms.Main RecommendationsDiagnosis: FND should be diagnosed based on positive signs rather than exclusion. This includes identifying inconsistencies and incongruencies in symptoms that differentiate them from other neurological conditions.Communication: The diagnosis of FND should be communicated to patients promptly and clearly upon diagnosis of the condition. Information provided should include the name of the condition, the basis on which the diagnosis has been made, key principles that can aid self-management, and shared planning of next steps in treatment or accessing treatment.Multidisciplinary Management: Across healthcare service models, treatment should involve a multidisciplinary team to address the multifaceted, and sometimes complex symptoms of FND.Role of General Practitioners (GPs): GPs are integral in the long-term management of FND, providing continuity of care, patient support and education, and facilitating access to specialist services. An informed GP can provide the patient with confidence and agency to be pro-active in their symptoms.Changes in Management as a result of the recommendationsThe recommendations advocate for a shift from a pure psychiatric framework to a multidisciplinary and person-centred approach. Employing the biopsychosocial framework can enhance patient outcomes, including addressing protective and risk factors for Aboriginal and Torres Strait Islander people.

The FORCAsT (FORest Canopy Atmosphere Transfer) model version 1.0 is updated to FORCAsT 2.0 by implementing five major changes, including (1) a change to the operator splitting, separating chemistry from emission and dry deposition, which reduces the run time of the gas-phase chemistry by 70 % and produces a more realistic in-canopy profile for isoprene; (2) a modification of the eddy diffusivity parameterization to produce greater and more realistic vertical mixing in the boundary layer, which ameliorates the unrealistic simulated end-of-day peaks in isoprene under well-mixed conditions and improves daytime air temperature; (3) updates to dry deposition velocities with available measurements; (4) implementation of the Reduced Caltech Isoprene Mechanism (RCIM) to reflect the current knowledge of isoprene oxidation; and (5) extension of the aerosol module to include isoprene-derived secondary organic aerosol (iSOA) formation. Along with the operator splitting, modified vertical mixing, and dry deposition, RCIM improves the estimation of first-generation isoprene oxidation products (methyl vinyl ketone and methacrolein) and some second-generation products (such as isoprene epoxydiols). Inclusion of isoprene in the aerosol module in FORCAsT 2.0 leads to a 7 % mass yield of iSOA. The most important iSOA precursors are IEPOX and tetrafunctionals, which together account for >86 % of total iSOA. The iSOA formed from organic nitrates is more important in the canopy, accounting for 11 % of the total iSOA. The tetrafunctionals compose up to 23 % of the total iSOA formation, highlighting the importance of the fate (i.e., dry deposition and gas-phase chemistry) of later-generation isoprene oxidation products in estimating iSOA formation.

The prion protein (PrP) is implicitly involved in the pathogenesis of transmissible spongiform encephalopathies (TSEs). The conversion of normal cellular PrP (PrP C), a protein that is predominantly α-helical, to a β-sheet-rich isoform (PrP Sc), which has a propensity to aggregate, is the key molecular event in prion diseases. During its short life span, PrP can experience two different pH environments; a mildly acidic environment, whilst cycling within the cell, and a neutral pH when it is glycosyl phosphatidylinositol (GPI)-anchored to the cell membrane. Ion mobility (IM) combined with mass spectrometry has been employed to differentiate between two conformational isoforms of recombinant Syrian hamster prion protein (SHaPrP). The recombinant proteins studied were α-helical SHaPrP(90-231) and β-sheet-rich SHaPrP(90-231) at pH 5.5 and pH 7.0. The recombinant proteins have the same nominal mass-to-charge ratio ( m/z) but differ in their secondary and tertiary structures. A comparison of traveling-wave (T-Wave) ion mobility and drift cell ion mobility (DCIM) mass spectrometry estimated and absolute cross-sections showed an excellent agreement between the two techniques. The use of T-Wave ion mobility as a shape-selective separation technique enabled differentiation between the estimated cross-sections and arrival time distributions (ATDs) of α-helical SHaPrP(90-231) and β-sheet-rich SHaPrP(90-231) at pH 5.5. No differences in cross-section or ATD profiles were observed between the protein isoforms at pH 7.0. The findings have potential implications for a new ante-mortem screening assay, in bodily fluids, for prion misfolding diseases such as TSEs. Two different prion protein (PrP) conformational isoforms, representative of healthy and diseased PrP, were analyzed by means of ion mobility mass spectrometry.